1. Home
  2. DNLI vs IBTA Comparison

DNLI vs IBTA Comparison

Compare DNLI & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • IBTA
  • Stock Information
  • Founded
  • DNLI 2013
  • IBTA 2011
  • Country
  • DNLI United States
  • IBTA United States
  • Employees
  • DNLI N/A
  • IBTA N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • IBTA
  • Sector
  • DNLI Health Care
  • IBTA
  • Exchange
  • DNLI Nasdaq
  • IBTA Nasdaq
  • Market Cap
  • DNLI 1.9B
  • IBTA 2.2B
  • IPO Year
  • DNLI 2017
  • IBTA 2024
  • Fundamental
  • Price
  • DNLI $13.21
  • IBTA $48.37
  • Analyst Decision
  • DNLI Strong Buy
  • IBTA Buy
  • Analyst Count
  • DNLI 15
  • IBTA 10
  • Target Price
  • DNLI $33.85
  • IBTA $74.60
  • AVG Volume (30 Days)
  • DNLI 1.3M
  • IBTA 459.0K
  • Earning Date
  • DNLI 05-06-2025
  • IBTA 05-14-2025
  • Dividend Yield
  • DNLI N/A
  • IBTA N/A
  • EPS Growth
  • DNLI N/A
  • IBTA 24.66
  • EPS
  • DNLI N/A
  • IBTA 2.03
  • Revenue
  • DNLI N/A
  • IBTA $369,501,000.00
  • Revenue This Year
  • DNLI N/A
  • IBTA $6.19
  • Revenue Next Year
  • DNLI $256.73
  • IBTA $15.05
  • P/E Ratio
  • DNLI N/A
  • IBTA $24.57
  • Revenue Growth
  • DNLI N/A
  • IBTA 7.20
  • 52 Week Low
  • DNLI $10.57
  • IBTA $31.40
  • 52 Week High
  • DNLI $33.33
  • IBTA $107.89
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 44.46
  • IBTA N/A
  • Support Level
  • DNLI $12.86
  • IBTA N/A
  • Resistance Level
  • DNLI $13.77
  • IBTA N/A
  • Average True Range (ATR)
  • DNLI 0.72
  • IBTA 0.00
  • MACD
  • DNLI -0.08
  • IBTA 0.00
  • Stochastic Oscillator
  • DNLI 32.29
  • IBTA 0.00

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About IBTA Ibotta Inc. Class A Common Stock

Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).

Share on Social Networks: